Drugs / AL-53817
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01454505 | Oct 2011 → Mar 2012 | allergic rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02079649 | Apr → Jul 2014 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL-53817 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01454505 ↗ |
| Route | Intranasal | “AL-53817 nasal spray solution, 1 spray to each nostril twice a day for 4 days.” NCT01454505 ↗ |